Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated ...

Wegovy pill, the first ever non-injectable GLP-1 for obesity, from drugmaker Novo Nordisk. Competitors like Eli Lilly are ...

The health-care corner of the US equity market has traditionally been viewed as defensive, thanks to steady growth and healthy dividend yields among the industry’s stalwarts. That narrative is ...

A new definition of obesity could nearly double the prevalence of U.S. adults with the condition, a new study published ...

The retrospective study could not determine whether some patients were more likely than others to keep off the weight.

Arrowhead Pharmaceuticals has reported early-phase data on a pair of gene silencing drug candidates in obesity, posting ...

Looking to overcome some of the limitations of existing obesity drugs, Alveus Therapeutics has debuted with nearly $160 ...

"Food noise" is the buzz in the battle against obesity. GLP1 injectables don't just decrease appetite, but also quiet "food ...

Obesity is one of the most serious and ubiquitous health problems worldwide. Obesity can be defined as a multifactorial ...

The consumer champion is now calling on the government to introduce a mandatory front-of-pack nutrition labelling scheme. It ...

Over 27 percent of adults worldwide with obesity qualify for GLP-1 weight loss medicines but access remains unequal.

Obesity is a complex, chronic condition that affects millions of Americans, and treating it often requires more than just ...